Acquiring Company
Tarsus Pharmaceuticals
Acquired Company
Alkeus Pharmaceuticals
IrvineCambridgeManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaDescription
On August 26, 2026, Tarsus Pharmaceuticals announced the acquisition of Alkeus Pharmaceuticals, receiving early termination approval from the FTC. The deal includes an upfront payment of $450 million and potential milestone payments of up to $350 million. This strategic move strengthens Tarsus's position in the ophthalmic therapeutic market and expands its product portfolio.
Don't miss Tarsus Pharmaceuticals's next move
Get an email the moment Tarsus Pharmaceuticals makes an acquisition, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Alkeus Pharmaceuticals?
Alkeus Pharmaceuticals was acquired by Tarsus Pharmaceuticals, based in Irvine. The deal was reported on August 26, 2026. Tarsus Pharmaceuticals, Inc. is a company specializing in biological products. They have shown substantial growth and have strategic initiatives in place, including the recent appointment of Dr. Tarsus Pharmaceuticals is publicly traded (TARS) and operates in Manufacturing.
When did Tarsus Pharmaceuticals acquire Alkeus Pharmaceuticals?
Tarsus Pharmaceuticals's acquisition of Alkeus Pharmaceuticals was reported on August 26, 2026. On August 26, 2026, Tarsus Pharmaceuticals announced the acquisition of Alkeus Pharmaceuticals, receiving early termination approval from the FTC. The deal includes an upfront payment of $450 million and potential milestone payments of up to $350 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Alkeus Pharmaceuticals do?
Alkeus Pharmaceuticals is a biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is focused on developing therapies for serious diseases of the eye with high unmet need. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.